Semaglutide for managing overweight and obesity: updated guidance (TA875)
Recommendation 1.1 has been updated to refer to the company’s commercial arrangement and section 2 has been updated to include the list price of semaglutide and to refer to the commercial arrangement.
Source:
National Institute for Health and Care Excellence
SPS commentary:
The Guardian has reported that semaglutide (Wegovy) is being made available in the UK as part of a “controlled and limited launch ”. It will be prescribed via specialist NHS weight management services alongside a reduced calorie diet and exercise from 4 September. Novo Nordisk has confirmed semaglutide is in short supply and said it expected it “to be constrained for the foreseeable future” but a “proportion of available supply” has been allocated to NHS services. The company said it is closely monitoring demand and working with regulators and providers. An NHS spokesperson said: “Despite global supply constraints, NHS England is taking action to begin implementing NICE guidance for weight management, while at the same time working to restore supplies of this class of drug for people with type 2 diabetes.”